We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02917993
Recruitment Status : Active, not recruiting
First Posted : September 28, 2016
Last Update Posted : February 21, 2023
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Incyte Corporation

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: Itacitinib Drug: Osimertinib Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Actual Study Start Date : December 20, 2016
Estimated Primary Completion Date : December 21, 2023
Estimated Study Completion Date : December 21, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Osimertinib

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Itacitinib + osimertinib Drug: Itacitinib
In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
Other Name: INCB039110

Drug: Osimertinib
Osimertinib 80 mg once daily (QD)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Phase 1: Frequency, severity, and duration of adverse events (AEs) [ Time Frame: From screening through 30-35 days after end of treatment, approximately 2 years. ]
  2. Phase 1: Number of subjects with dose-limiting toxicities (DLTs) [ Time Frame: Day 1 through Day 28 ]
  3. Phase 2: Objective response rate (ORR) based on RECIST v1.1 [ Time Frame: Screening and 8-week intervals throughout the study, approximately 2 years. ]
    ORR defined as the percentage of subjects who have a confirmed best overall response of complete response (CR) or partial response (PR).


Secondary Outcome Measures :
  1. Phase 1 and Phase 2: Maximum plasma concentration (Cmax) of itacitinib and osimertinib when administered in combination [ Time Frame: Measured at protocol-defined study visits from Cycle 1 Day 1 through Cycle 1 Day 28. ]
  2. Phase 1 and Phase 2: Area under the plasma concentration-time curve (AUC) of Itacitinib and osimertinib when administered in combination [ Time Frame: Measured at protocol-defined study visits from Cycle 1 Day 1 through Cycle 1 Day 28. ]
  3. Phase 2: Depth of response (DpR) based on RECIST v1.1 [ Time Frame: Screening and 8-week intervals throughout the study, approximately 2 years. ]
    Defined as the percentage of maximal tumor shrinkage observed at the lowest point (nadir) compared with baseline.

  4. Phase 2: Progression-free survival (PFS) [ Time Frame: Interval from the first day of study treatment until disease progression or death due to any cause, approximately 3 years. ]
  5. Phase 2: Overall survival (OS) [ Time Frame: Interval from the first day of study treatment until death due to any cause, approximately 3 years. ]
  6. Phase 2: Frequency, severity, and duration of AEs [ Time Frame: From screening through 30-35 days after end of treatment, approximately 2 years. ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older at screening; outside the U.S. and European Union, an older limit could apply depending on local regulation (eg, 19 years and older for South Korea and 20 years and older for Taiwan).
  • Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC.

  • Documented evidence of somatic activating mutation in EGFR (eg, G719X, exon 19 deletion, L858R, L861Q) in a tumor tissue sample. If a tissue sample is not available, then EGFR mutation status may be determined from circulating tumor DNA obtained from a blood sample using a validated or approved test kit.

    • Phase 1: Subjects must have previously received and progressed on or after treatment with an EGFR tyrosine kinase inhibitor (TKI). Additional lines of systemic therapy including investigational agents for locally advanced or metastatic NSCLC are allowed.

    • Phase 2: Subjects must not have received more than 1 prior line of therapy for locally advanced or metastatic NSCLC. First-line treatment must include an EGFR TKI, and subjects must have documented disease progression during or following treatment. Subjects with disease that progressed more than 6 months after completion of neoadjuvant/adjuvant chemotherapy or chemoradiation therapy are eligible if they received an EGFR TKI as first-line treatment for advanced NSCLC.

      • Subjects must have evidence of a T790M mutation in tumor tissue or plasma obtained after disease progression during or after treatment with an EGFR TKI. T790M mutation status from a local laboratory is acceptable; however, a tumor tissue sample or plasma sample suitable for centralized T790M mutation analysis must be available.
  • Radiographically measurable or evaluable disease per RECIST v1.1.

Exclusion Criteria:

  • Known CNS metastases, unless stable and asymptomatic. Subjects with CNS metastases may be eligible for the study, provided:

    • There is no evidence of new or enlarging CNS metastasis or new neurological symptoms attributable to CNS metastases.
    • Subjects who are receiving corticosteroids must be on a stable or decreasing dose for at least 4 weeks before first dose of study treatment.
  • Laboratory parameters outside the protocol-defined range.
  • Clinically significant abnormalities found on an ECG.
  • Clinically significant or uncontrolled cardiac disease.
  • Past history of interstitial lung disease (ILD), drug induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.
  • Current or previous other malignancy within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive malignancy.
  • Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or hormonal therapy).
  • Any previous use of Janus kinase (JAK) inhibitor, osimertinib, or other EGFR-directed therapy for T790M-mt NSCLC.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02917993


Locations
Show Show 31 study locations
Sponsors and Collaborators
Incyte Corporation
AstraZeneca
Investigators
Layout table for investigator information
Study Director: Peter Langmuir Incyte Corporation
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT02917993    
Other Study ID Numbers: INCB 39110-207
First Posted: September 28, 2016    Key Record Dates
Last Update Posted: February 21, 2023
Last Verified: February 2023
Keywords provided by Incyte Corporation:
non-small cell lung cancer
locally advanced
metastatic
epidermal growth factor receptor (EGFR) inhibition
Janus kinase inhibition
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
 Carcinoma, Bronchogenic
Bronchial Neoplasms
Osimertinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action